Shares of Bristol Myers Squibb Co. rallied 3.59% to $54.29 Monday, on what proved to be an all-around grim trading session ...
24/7 Wall St. on MSN
Here Are Monday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, GE Vernova, KLA Corp., Klaviyo, Las Vegas Sands, ServiceNow, and More
Futures are trading higher on Monday as we head into the final trading weeks of 2025. All of the major indices were hit hard ...
If you are wondering whether Bristol-Myers Squibb is quietly becoming a value opportunity or just a classic value trap, you ...
Bank of America upgrades Bristol Myers to Buy, lifting its price target to $61 on pipeline catalysts, valuation support, and ...
Fintel on MSN
Guggenheim upgrades Bristol-Myers Squibb (BMY)
Fintel reports that on December 12, 2025, Guggenheim upgraded their outlook for Bristol-Myers Squibb (NYSE:BMY) from Neutral ...
Neutral sector-focused overview describing factual commentary surrounding Bristol Myers Squibb within the wider ...
Bristol-Myers Squibb faces patent cliff risks despite strong drug revenues and a 4.8% yield. Click here to read my latest analysis of BMY stock.
The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...
Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for ...
Bristol-Myers Squibb Company (NYSE:BMY) is one of the best pharma stocks to invest in. On December 4, Jefferies reiterated a ...
Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.
Bristol Myers Squibb raised its quarterly dividend by 1.6% to 63 cents a share from 62 cents a share. The new payout, equal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback